Insider Trades23 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 2,080 | $8.51 | $532.0M | -15.85% | +274.47% | $17.7K | +0.00% | 10b5-1 | — |
| Jul 8, 2026 | Sell | CTNM | Carmine N. Stengone | CEO and President | 5,000 | $8.51 | $532.0M | -15.85% | +274.47% | $42.5K | +0.00% | 10b5-1 | — |
| Jun 30, 2026 | Sell | CTNM | Carmine N. Stengone | CEO and President | 20,000 | $8.54 | $532.0M | -15.85% | +274.47% | $170.8K | +0.00% | 10b5-1 | — |
| Jun 30, 2026 | Sell | CTNM | Tim Watkins | CMO & Head of Development | 21,666 | $10.26 | $532.0M | -15.85% | +274.47% | $222.3K | +0.00% | 10b5-1 | — |
| Jun 30, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 70,188 | $8.95 | $532.0M | -15.85% | +274.47% | $627.9K | -0.52% | 10b5-1 | — |
| Jun 1, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $13.16 | $532.0M | -15.85% | +274.47% | $54.9K | -2.91% | 10b5-1 | — |
| May 1, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $13.12 | $532.0M | -15.85% | +274.47% | $54.7K | -1.43% | 10b5-1 | — |
| Apr 6, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $13.43 | $532.0M | -15.85% | +274.47% | $56.0K | -2.75% | 10b5-1 | — |
| Mar 2, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $15.01 | $532.0M | -15.85% | +274.47% | $62.6K | -2.67% | 10b5-1 | — |
| Mar 2, 2026 | Sell | CTNM | Tim Watkins | CMO & Head of Development | 7,222 | $9.76 | $532.0M | -15.85% | +274.47% | $70.5K | +0.00% | 10b5-1 | — |
| Feb 24, 2026 | Sell | CTNM | Carmine N. Stengone | CEO and President | 14,200 | $8.64 | $532.0M | -15.85% | +274.47% | $122.7K | +0.00% | 10b5-1 | — |
| Feb 24, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 16,248 | $8.52 | $532.0M | -15.85% | +274.47% | $138.4K | +0.00% | 10b5-1 | — |
| Feb 19, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 200 | $8.51 | $532.0M | -15.85% | +274.47% | $1.7K | +0.00% | 10b5-1 | — |
| Feb 11, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 800 | $8.51 | $532.0M | -15.85% | +274.47% | $6.8K | +0.00% | 10b5-1 | — |
| Feb 11, 2026 | Sell | CTNM | Carmine N. Stengone | CEO and President | 800 | $8.63 | $532.0M | -15.85% | +274.47% | $6.9K | +0.00% | 10b5-1 | — |
| Feb 3, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $14.94 | $532.0M | -15.85% | +274.47% | $62.3K | -1.31% | 10b5-1 | — |
| Jan 28, 2026 | Sell | CTNM | Tim Watkins | CMO & Head of Development | 7,222 | $9.34 | $532.0M | -15.85% | +274.47% | $67.4K | +0.00% | 10b5-1 | — |
| Jan 5, 2026 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $10.44 | $532.0M | -15.85% | +274.47% | $43.5K | -1.28% | 10b5-1 | — |
| Dec 29, 2025 | Sell | CTNM | Tim Watkins | CMO & Head of Development | 7,222 | $8.28 | $532.0M | -15.85% | +274.47% | $59.8K | +0.00% | 10b5-1 | — |
| Dec 23, 2025 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 4,170 | $12.23 | $532.0M | -15.85% | +274.47% | $51.0K | -2.47% | 10b5-1 | — |
| Nov 25, 2024 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 1,010 | $16.02 | $532.0M | -15.85% | +274.47% | $16.2K | -0.60% | 10b5-1 | — |
| Nov 18, 2024 | Sell | CTNM | Daniel S. Lorrain | Chief Scientific Officer | 6,190 | $16.38 | $532.0M | -15.85% | +274.47% | $101.4K | -1.79% | 10b5-1 | — |
| Aug 13, 2024 | Buy | CTNM | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 12,800 | $1.01 | $532.0M | -15.85% | +274.47% | $12.9K | +7.93% | — | — |